Palindromic Rheumatism Symptoms
Cross-source consensus on Palindromic Rheumatism Symptoms from 1 sources and 5 claims.
1 sources · 5 claims
Benefits
Highlighted claims
- Over 24 months, remission occurred in 55.9% of abatacept participants versus 22.9% of hydroxychloroquine participants. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
- Attack intensity decreased to a median of 4.0 with abatacept but remained 7.0 with hydroxychloroquine. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
- Abatacept produced clearer benefits for remission and attack intensity than hydroxychloroquine. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
- Attack frequency decreased in both treatment groups, but median attack number did not differ significantly between groups. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
- Attacks lasting less than 24 hours were more common with abatacept than hydroxychloroquine over 24 months. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial